News and Updates

Despite successful Phase 3 trials and new FDA guidance, psilocybin therapy faces adoption hurdles. Explore the clinical and scaling challenges ahead.

The FDA has cleared an IND application for ATR-1072, a novel treatment for PRKAG2 syndrome. Learn about this breakthrough in genetic cardiac therapy.

A new clinical trial for a novel mesothelioma drug shows promising results. Learn how this targeted therapy could improve survival for lung cancer patients.

Discover how AI is revolutionizing clinical trial finance by optimizing budgets, reducing risk, and accelerating medical research through predictive data.

Can viruses stop UTIs? Hungarian researchers join a landmark European trial testing phage therapy as a solution for recurrent, antibiotic-resistant infections.

Mesoblast hits a major milestone with 300 patients enrolled in its Phase 3 trial for rexlemestrocel-L, a potential breakthrough for chronic back pain.

The FDA has approved a subcutaneous injection for Leqembi, offering a faster, more convenient treatment option for early-stage Alzheimer’s patients.

Elevar Therapeutics faces a major setback as recurring manufacturing failures lead to FDA delays, highlighting critical gaps in drug production compliance.

The 2024 McDonald Criteria update mandates urgent audits for MS clinical trials. Learn how these new diagnostic standards impact study data and compliance.

The FDA has issued strict new guidance for psychedelic clinical trials, focusing on rigorous study design, patient safety, and improved data integrity.